Finding the best antibiotic treatment for certain bloodstream infections
Official title: Identifying Optimal Antibiotic Treatment for Non-CTX-M-Producing ESBL Bloodstream Infections
Funded at Johns Hopkins University · NIH-10991031 · Data updated 2026-11-12
This study is looking at how different kinds of enzymes in bacteria can change how well antibiotics work for people with bloodstream infections, so we can find the best treatment for each person and help them recover better.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | November 21, 2023 |
| Project end | October 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $204,688 |
| NIH project number | 5R21AI173475-02 |
| Project ID | NIH-10991031 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacterales.
✕Less likely to help
Patients with bloodstream infections not caused by ESBL-producing bacteria may not benefit from this research.
What this research studies
This research investigates how different types of extended-spectrum β-lactamase (ESBL) enzymes affect the effectiveness of antibiotic treatments for bloodstream infections. The study aims to identify the optimal antibiotic therapy based on the specific ESBL enzyme present in the bacteria, which could lead to more targeted and effective treatments. By analyzing patient outcomes and the types of ESBL enzymes, the researchers hope to improve treatment protocols and reduce mortality rates associated with these infections.
Why it matters
Potential benefit: If successful, this research could lead to more effective antibiotic treatments for patients suffering from bloodstream infections caused by ESBL-producing bacteria.
How similar studies have gone: Previous research has shown success in optimizing antibiotic treatments based on resistance mechanisms, indicating potential for this approach to improve outcomes for ESBL infections.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Tamma, Pranita — Johns Hopkins University
- Study coordinator: Tamma, Pranita
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.